Left Atrial Appendage Closure Is Safe with the New Devices

Left atrial appendage closure (LAAC) in non-valvular atrial fibrillation with high risk of bleeding has shown promising results with first generation devices (with the Watchman) in the different studies.

El cierre de orejuela es seguro con los nuevos dispositivos

At present, we have a more modern device, the Watchman FLX, but we do not have much information about it. 

To gather more data, researchers looked at 200 consecutive patients from the FLX‐IEST Registry (Watchman FLX data from two high‐volume Sicilian centers) receiving LAAC with Watchman FLX.

Mean age was 77, 67% were men, 57% had kidney function deterioration, 41% were diabetic, 55% had coronary artery disease, 18% were in functional class III, 55% had cardiac failure, 47% ejection fraction, 29% stroke or transient ischemic attack, 56% prior bleeding. 

CHA2DS2‐VASc score was 5 and HAS‐BLED score was 4.

LAAC indications were symptomatic hemorrhage, need for triple antithrombotic therapy, gastrointestinal bleeding, and oral anticoagulation intolerance. 

93% was guided by transesophageal eco-Doppler, 48% was done under general anesthesia, 45% under conscious sedation and 7% under local anesthesia. 

Read also: Ticagrelor Monotherapy: Valid after 12 Months?

Procedural success was 99.5%. >5 mm leak was seen in one patient only and <5 mm in two patients, and there was no embolization. Major bleeding rate was 1%; there was one death related to major bleeding. 

At discharge, 85% received dual antiplatelet therapy (DAPT).

At 272±173 day follow up, there was 4.1% major bleeding, 0.6% fatal bleeding and 2.3% non-device-related stroke. 

Conclusion

This study showed a higher procedural success rate with Watchman-FLX in a high-risk population. According to author experience, the main advantage included easy implantation and repositioning, absence of embolization, good left atrial appendage sealing and low complications rate at follow up. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Real‐world experience with the new Watchman FLX device: Data from two high‐volume Sicilian centers. The FLX‐iEST registry.

Reference: Giampiero Vizzari, et al. Catheter Cardiovasc Interv. 2022;100:154–160.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

 The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...